Glancy Prongay & Murray LLP Announces Investigation on Behalf of American Renal Associates Holdings, Inc. Investors

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf
of American Renal Associates Holdings, Inc. investors (“American Renal”
or the “Company”) (NYSE: ARA)
concerning the Company and its officers’ possible violations of federal
securities laws.

If you are a shareholder who suffered a loss, click here to
participate.

If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, at
310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected],
or visit our website at www.glancylaw.com.

On March 8, 2019, American Renal announced the postponement of the
release of its fourth quarter and year-end 2018 earnings report, as well
as the filing of their 2018 Form 10-K. Previously, the SEC had requested
in October 2018 that the Company provide documentation and information
regarding revenue recognition, collections, and other related matters.
As a result of this SEC request, American Renal formed an Audit
Committee that has been examining the Company’s revenue recognition
methods and accounting practices. Due to this internal investigation by
the Audit Committee and the impact the information found would
potentially have on these pending earning reports, the Company has
delayed the filing of their 2018 Form 10-K and announced possible
further adjustments for their previously reported fiscal years ranging
from 2014 to 2017, as well as the still delayed fiscal report for 2018.

On this news, shares of American Renal fell over 21% during intraday
trading, thereby injuring investors.

If you purchased American Renal securities, have information, or would
like to learn more about these claims, or have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East,
Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at
888-773-9224, or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number, and the number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190308005531/en/